CTIBiotech, an innovative R&D firm based in Lyon, France, is using CELLINK’s BIO X 3D bioprinter to produce in vitro full skin models from human cells. These bioprinted human skin models, which include sebaceous glands, immune cells or melanocytes, are more physiologically relevant. These improved models enable researchers to investigate sebum production, acne, or atopic dermatitis.
Additionally, with CTIBIOTECH able to produce over one hundred artificial skin constructs (1 cm2 in size), it is possible for them to have a high-throughput approach for screening of active ingredients in topical products, aesthetic or medical devices for skincare.
Tissue-engineering breakthroughs like this are propelling the industry forward, reducing its dependence on animal experimentation, while driving down development costs and paving the way for safer and more efficacious beauty and dermatological products.
The $40 billion cosmetic industry is increasingly innovating using in vitro technologies as alternatives to animal experimentation for efficacy and safety testing skincare and beauty products. Thankfully, advances in tissue engineering, such as the ability to bioprint human tissue models in the lab, have unlocked promising long-term-solutions.